- Home
- ABUS vs RGNX Comparison
ABUS vs RGNX Comparison
Compare ABUS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABUS | RGNX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.5M | 678.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ABUS | RGNX |
|---|---|---|
| Price | $4.84 | $15.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $5.00 | ★ $30.78 |
| AVG Volume (30 Days) | ★ 1.4M | 684.2K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,606,000.00 | ★ $161,318,000.00 |
| Revenue This Year | $125.30 | $132.80 |
| Revenue Next Year | N/A | $45.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 116.64 | 91.30 |
| 52 Week Low | $2.71 | $5.04 |
| 52 Week High | $5.10 | $15.41 |
Technical Indicators
Market Signals| Indicator | ABUS | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 62.10 |
| Support Level | $4.65 | $12.87 |
| Resistance Level | $5.05 | $14.65 |
| Average True Range (ATR) | 0.22 | 0.95 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 67.46 | 79.01 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.